Tokyo, Japan

Yuki Taya

This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: The University of Tokyo, Nec Corporation. Active years: 2019-2026.

USPTO Granted Patents = 3 

% Patents Active = 66.7

 

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2026

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yuki Taya: Innovator in Medical Nutrition and Hematology

Introduction

Yuki Taya is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the fields of medical nutrition and hematology through her innovative patents. With a total of 3 patents, Taya's work focuses on developing solutions for serious health conditions.

Latest Patents

Taya's latest patents include a composition for treating adult T cell leukemia/lymphoma and a method for producing the same. This nutrition formulation is designed to be substantially free of at least one of valine and methionine, allowing for parenteral or enteral administration. The formulation is capable of supplying sufficient nutrients to sustain life for at least three weeks through successive administration. Additionally, she has developed a composition aimed at decreasing hematopoietic stem cells, providing a technique that replaces radiation exposure in reducing or eliminating these cells in the human body.

Career Highlights

Yuki Taya is affiliated with The University of Tokyo, where she continues her research and development in medical innovations. Her work has garnered attention for its potential impact on treating complex medical conditions.

Collaborations

Taya collaborates with notable colleagues, including Hiromitsu Nakauchi and Satoshi Yamazaki, who contribute to her research endeavors.

Conclusion

Yuki Taya's innovative work in medical nutrition and hematology showcases her commitment to advancing healthcare solutions. Her patents reflect a dedication to improving treatment options for patients facing serious health challenges.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…